featured
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin in Primary Cardiovascular Prevention
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes Care
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
Diabetes Care 2021 Mar 02;[EPub Ahead of Print], A Cahn, I Raz, LA Leiter, O Mosenzon, SA Murphy, EL Goodrich, I Yanuv, A Rozenberg, DL Bhatt, DK McGuire, JPH Wilding, IAM Gause-Nilsson, AM Langkilde, MS Sabatine, SD WiviottFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.